CNBC's Meg Tirrell reports on hottest new technologies from the annual meeting of the American Society of Hematology.
Jim Phillips, CEO of Midatech, talks about the company's IPO and its nanoparticle technology which could help cure diseases such as cancer.
Drug giant Sanofi is juggling legal and regulatory issues surrounding three cases involving alleged payments or inducements to medical providers.
The American Society of Hematology is holding a massive conference in San Francisco on Saturday. CNBC's Meg Tirrell tells why pharma and biotech investors are paying close attention.
A lawsuit accuses drug maker Sanofi and top executives, including its ousted CEO, of a million-dollar kickback scheme to promote diabetes drug sales.
The tax inversion announcement seriously reduced the likelihood of the Pfizer AstraZeneca deal going ahead says CNBC's Catherine Boyle.
Pascal Soriot, CEO of Astrazeneca, says there will be less need for mergers and acquisitions as the company's internal drug pipeline is strong.
Discussing a possible British exit from the European Union, Pascal Soriot, CEO of Astrazeneca, says he is a believer in Europe and immigration is key to getting the best talent for his company.
Mike Ward, global director of content at SCRIP Intelligence, says pharmaceutical companies could look towards the technology sector for interesting mergers, acquisitions or partnerships.
Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.
American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".
Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?
CNBC's Meg Tirrell, and Nancy Goodman, Kids v. Cancer founder, discuss the initiative to encourage drug companies to develop treatments for children with cancer and other rare diseases.
Kids facing cancer need access to promising — albeit unapproved — drugs, say these parents, who have faced the battle with their children firsthand.
Sanofi's global R&D President Dr. Elias Zerhouni, says he wouldn't trade his company's pipeline with anybody in the industry, and discusses the upcoming drug launches.
AstraZeneca said it had made good progress in developing a pipeline of new drugs.
NIH's Dr. Francis Collins and Milken Institute Chairman Mike Milken make the case for medical research funding to stop outbreaks like Ebola.
Shares of Zoetis are on the move after Actavis announced it is buying Allergan. Mark Schoenbaum, Evercore ISI senior managing director, discusses if the company could be bought.
Áine Slowey, senior analyst at Datamonitor Healthcare, discusses Actavis' decision to buy Allergan for $65.5 billion, saying that Actavis has demonstrated a "strong commitment" to R&D.
Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.